Open-label, single-center, randomized and parallel-group study to compare the effect of hydrofluoroalkane-134a beclomethasone dipropionate (HFA-BDP) and that of fluticasone propionate dry powder inhaler (FP-DPI) on large and small airways involvement in bronchial asthma.

Trial Profile

Open-label, single-center, randomized and parallel-group study to compare the effect of hydrofluoroalkane-134a beclomethasone dipropionate (HFA-BDP) and that of fluticasone propionate dry powder inhaler (FP-DPI) on large and small airways involvement in bronchial asthma.

Completed
Phase of Trial: Phase IV

Latest Information Update: 12 May 2016

At a glance

  • Drugs Beclometasone (Primary) ; Fluticasone propionate
  • Indications Asthma
  • Focus Therapeutic Use
  • Most Recent Events

    • 22 Dec 2009 Status changed from active, no longer recruiting to completed as reported by University Hospital Medical Information Network - Japan.
    • 17 Jul 2009 Actual initiation date (Mar 2007) added as reported by University Hospital Medical Information Network - Japan record.
    • 17 Jul 2009 Status changed from not yet recruiting to active, no longer recruiting as reported by University Hospital Medical Information Network - Japan record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top